News | November 15, 2023
JB Pharma Q2 FY24 PAT up 36% to Rs. 151 Cr
Reports revenue growth of 9% to INR 882 crores in Q2 FY24
Reports revenue growth of 9% to INR 882 crores in Q2 FY24
EBITDA for Q2 FY24 at Rs. 71.2 crore as compared to Rs. 79.9 crore QoQ
Phase 3 data expected in the second half of 2024
Narayana Hrudayalaya has reported total income of Rs. 1323.64 crores during the period ended September 30, 2023
Yesafili, received marketing authorization approval from the European Commission for the European Union
Sales in the US region grew well, partially offset by the decline in the LATAM and European regions
European operations' revenue grew 58.4% to Rs 599.7 crore
General Medicine grows 5% and Vaccines 10% led by Shingrix
Q2FY24 EBITDA up by 105% y-o-y at Rs. 28 crore
Dr. Reddy’s maintains that the allegations against it lack merit and will vigorously defend the litigation
Subscribe To Our Newsletter & Stay Updated
